Clopidogrel ratiopharm

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

clopidogrel (as hydrogen sulfate)

Available from:

Teva B.V.

ATC code:

B01AC04

INN (International Name):

clopidogrel

Therapeutic group:

Antitrombotična sredstva

Therapeutic area:

Myocardial Infarction; Acute Coronary Syndrome; Peripheral Vascular Diseases; Stroke

Therapeutic indications:

Secondary prevention of atherothrombotic events Clopidogrel is indicated in:Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Za odrasle bolnike, ki trpijo za akutni koronarni sindrom:Non-ST segmentu višinskih akutni koronarni sindrom (nestabilna angina pektoris ali ne-Q-val, miokardni infarkt), vključno z bolniki, ki opravljajo stent umestitev po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilne kisline (ASA). ST segmentu višinskih akutni miokardni infarkt, v kombinaciji s ASA v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. Preprečevanje atherothrombotic in thromboembolic dogodkov v atrijska fibrillationIn odraslih bolnikov z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke, niso primerni za zdravljenje z antagonisti Vitamina K (VKA) in ki imajo nizko tveganje krvavitve, clopidogrel je indiciran v kombinaciji s ASA za preprečevanje atherothrombotic in thromboembolic dogodkov, vključno z možgansko kap.

Product summary:

Revision: 14

Authorization status:

Pooblaščeni

Authorization date:

2015-02-18

Patient Information leaflet

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Klopidogrel ratiopharm 75 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki
klopidogrelijevega sulfata).
Pomožna snov z znanim učinkom:
Ena filmsko obložena tableta vsebuje 59,05 mg laktoze (v obliki
monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Nežno rožnate do rožnate filmsko obložene tablete, v obliki
kapsule. Ena stran tablete ima vtisnjeno
številko »93«, druga stran tablete pa številko »7314«.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
_Sekundarno preprečevanje aterotrombotičnih dogodkov_
Klopidogrel je indiciran pri:
•
odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35
dni), ishemično
možgansko kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano
periferno arterijsko boleznijo.
•
odraslih bolnikih z akutnim koronarnim sindromom;
−
akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina
ali miokardni
infarkt brez Q zobca), vključno z bolniki, katerim je bila vstavljena
opornica po perkutani
koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA),
−
akutni miokardni infarkt z elevacijo ST spojnice v kombinaciji z ASA
pri bolnikih, pri
katerih se izvaja perkutana koronarna intervencija (vključno z
bolniki, katerim je bila
vstavljena opornica), ali pri bolnikih, ki se zdravijo z zdravili in
so primerni za
trombolitično/fibrinolitično zdravljenje;
_Pri bolnikih z zmernim do zelo tveganim_
_prehodnim ishemičnim napadom (TIA – Transient Ischemic _
_Attack) ali manjšo ishemično možgansko kapjo (IMK) _
Klopidogrel je v kombinaciji z ASA indiciran pri:
•
odraslih bolnikih z zmernim do zelo tveganim TIA (ocena ABCD2
1
≥ 4) ali manjšo IMK (ocena
NIHSS
2
≤ 3) v 24 urah po TIA ali IMK.
_Preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri
atrijski fibrilaciji _
Pri odraslih bolnikih z atrijsko f
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Klopidogrel ratiopharm 75 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki
klopidogrelijevega sulfata).
Pomožna snov z znanim učinkom:
Ena filmsko obložena tableta vsebuje 59,05 mg laktoze (v obliki
monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Nežno rožnate do rožnate filmsko obložene tablete, v obliki
kapsule. Ena stran tablete ima vtisnjeno
številko »93«, druga stran tablete pa številko »7314«.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
_Sekundarno preprečevanje aterotrombotičnih dogodkov_
Klopidogrel je indiciran pri:
•
odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35
dni), ishemično
možgansko kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano
periferno arterijsko boleznijo.
•
odraslih bolnikih z akutnim koronarnim sindromom;
−
akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina
ali miokardni
infarkt brez Q zobca), vključno z bolniki, katerim je bila vstavljena
opornica po perkutani
koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA),
−
akutni miokardni infarkt z elevacijo ST spojnice v kombinaciji z ASA
pri bolnikih, pri
katerih se izvaja perkutana koronarna intervencija (vključno z
bolniki, katerim je bila
vstavljena opornica), ali pri bolnikih, ki se zdravijo z zdravili in
so primerni za
trombolitično/fibrinolitično zdravljenje;
_Pri bolnikih z zmernim do zelo tveganim_
_prehodnim ishemičnim napadom (TIA – Transient Ischemic _
_Attack) ali manjšo ishemično možgansko kapjo (IMK) _
Klopidogrel je v kombinaciji z ASA indiciran pri:
•
odraslih bolnikih z zmernim do zelo tveganim TIA (ocena ABCD2
1
≥ 4) ali manjšo IMK (ocena
NIHSS
2
≤ 3) v 24 urah po TIA ali IMK.
_Preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri
atrijski fibrilaciji _
Pri odraslih bolnikih z atrijsko f
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-03-2024
Public Assessment Report Public Assessment Report Bulgarian 11-03-2015
Patient Information leaflet Patient Information leaflet Spanish 26-03-2024
Public Assessment Report Public Assessment Report Spanish 11-03-2015
Patient Information leaflet Patient Information leaflet Czech 26-03-2024
Public Assessment Report Public Assessment Report Czech 11-03-2015
Patient Information leaflet Patient Information leaflet Danish 26-03-2024
Public Assessment Report Public Assessment Report Danish 11-03-2015
Patient Information leaflet Patient Information leaflet German 26-03-2024
Public Assessment Report Public Assessment Report German 11-03-2015
Patient Information leaflet Patient Information leaflet Estonian 26-03-2024
Public Assessment Report Public Assessment Report Estonian 11-03-2015
Patient Information leaflet Patient Information leaflet Greek 26-03-2024
Public Assessment Report Public Assessment Report Greek 11-03-2015
Patient Information leaflet Patient Information leaflet English 26-03-2024
Public Assessment Report Public Assessment Report English 11-03-2015
Patient Information leaflet Patient Information leaflet French 26-03-2024
Public Assessment Report Public Assessment Report French 11-03-2015
Patient Information leaflet Patient Information leaflet Italian 26-03-2024
Public Assessment Report Public Assessment Report Italian 11-03-2015
Patient Information leaflet Patient Information leaflet Latvian 26-03-2024
Public Assessment Report Public Assessment Report Latvian 11-03-2015
Patient Information leaflet Patient Information leaflet Lithuanian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-03-2024
Public Assessment Report Public Assessment Report Lithuanian 11-03-2015
Patient Information leaflet Patient Information leaflet Hungarian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 26-03-2024
Public Assessment Report Public Assessment Report Hungarian 11-03-2015
Patient Information leaflet Patient Information leaflet Maltese 26-03-2024
Public Assessment Report Public Assessment Report Maltese 11-03-2015
Patient Information leaflet Patient Information leaflet Dutch 26-03-2024
Public Assessment Report Public Assessment Report Dutch 11-03-2015
Patient Information leaflet Patient Information leaflet Polish 26-03-2024
Public Assessment Report Public Assessment Report Polish 11-03-2015
Patient Information leaflet Patient Information leaflet Portuguese 26-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 26-03-2024
Public Assessment Report Public Assessment Report Portuguese 11-03-2015
Patient Information leaflet Patient Information leaflet Romanian 26-03-2024
Public Assessment Report Public Assessment Report Romanian 11-03-2015
Patient Information leaflet Patient Information leaflet Slovak 26-03-2024
Public Assessment Report Public Assessment Report Slovak 11-03-2015
Patient Information leaflet Patient Information leaflet Finnish 26-03-2024
Public Assessment Report Public Assessment Report Finnish 11-03-2015
Patient Information leaflet Patient Information leaflet Swedish 26-03-2024
Public Assessment Report Public Assessment Report Swedish 11-03-2015
Patient Information leaflet Patient Information leaflet Norwegian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 26-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 26-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 26-03-2024
Patient Information leaflet Patient Information leaflet Croatian 26-03-2024
Public Assessment Report Public Assessment Report Croatian 09-10-2023

Search alerts related to this product